Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.300
-0.080 (-2.37%)
Nov 18, 2026, 10:41 AM EST - Market open
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $1.48M in the quarter ending September 30, 2026, a decrease of -55.11%. This brings the company's total for the last twelve months to $6.40M, down -59.34% year-over-year. In the year 2025, Aclaris Therapeutics had annual revenue of $7.83M, down -58.19%. That makes Aclaris Therapeutics the 39,160th largest company in the world by revenue and 5,168th in the United States.
Revenue (ttm)
$6.40M
Revenue Growth
-59.34%
P/S Ratio
83.75
Revenue / Employee
$87,685
Employees
73
Market Cap
523.42M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.83M | -10.89M | -58.19% |
| Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
| Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
| Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
| Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
| Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
| Dec 31, 2019 | 4.23M | -1.92M | -31.28% |
| Dec 31, 2018 | 6.15M | 4.47M | 265.48% |
| Dec 31, 2017 | 1.68M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 163.30M |
| Zevra Therapeutics | 147.76M |
| Ginkgo Bioworks Holdings | 130.75M |
| Wave Life Sciences | 70.92M |
| Orchestra BioMed Holdings | 31.21M |
| Iambic Therapeutics | 18.25M |
| Crescent Biopharma | 15.00M |
ACRS News
- 1 day ago - Aclaris Therapeutics price target lowered to $12 from $13 at Canaccord - TheFly
- 1 day ago - Aclaris shares drop 1.5% after Phase 2 trial fails to meet endpoints - TheFly
- 1 day ago - Aclaris Therapeutics downgraded to Neutral at Wedbush after AD trial miss - TheFly
- 1 day ago - Aclaris Therapeutics downgraded to Neutral from Outperform at Wedbush - TheFly
- 2 days ago - Aclaris Therapeutics initiates ALPHA trial of modzatinib - TheFly
- 2 days ago - Aclaris Therapeutics Transcript: Jefferies Global Healthcare Conference - Transcripts
- 2 days ago - Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP) - GlobeNewsWire
- 2 days ago - Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD) - GlobeNewsWire